

Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 10 March 2026.

13 March 2026

Physiomics plc

("Physiomics" or the "Company")

Result of WRAP Retail Offer

Physiomics plc (AIM: PYC), is pleased to announce, further to the announcements made on 10 March 2026, the completion of the WRAP Retail Offer, at the same issue price as the previously announced Placing (together the "Fundraise"). The WRAP Retail Offer, which closed at 4.30 p.m. on 12 March 2026, has raised aggregate gross proceeds of £223,279.48 through the issue of a total of 74,426,493 new Ordinary Shares, alongside the previously announced Placing which raised gross proceeds of £449,999.88. The WRAP Retail Offer was oversubscribed.

The Fundraise, which is conditional on certain resolutions being passed at the General Meeting and on Admission, raised gross proceeds of, in aggregate, £673,279.36, via the issue of 149,999,960 Placing Shares pursuant to the Placing and 74,426,493 WRAP Retail Offer Shares pursuant to the WRAP Retail Offer.

A further announcement regarding the enlarged issued share capital for the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules will be made following completion of the Placing and the WRAP Retail Offer.

The new Ordinary Shares to be issued pursuant to the WRAP Retail Offer (which is conditional on the Placing and the passing of the resolutions at the General Meeting) will be issued free of all liens, charges and encumbrances and will, on Admission, rank *pari passu* in all respects with the new Ordinary Shares to be issued pursuant to the Placing and the Company's existing Ordinary Shares.

EXPECTED TIMETABLE OF EVENTS

Latest time for receipt of Forms of Proxy and electronic proxy appointments:	10.00 a.m. on Wednesday 1 April 2026
General Meeting:	10.00 a.m. on Tuesday 7 April 2026
Record Date for the Sub-Division	11.59 p.m. on Tuesday 7 April 2026
Effective Date of the Sub-Division	11.59 p.m. on Tuesday 7 April 2026
Admission of new Ordinary Shares and dealings commence on AIM	8.00 a.m. on Wednesday 8 April 2026

For further information, please contact:

Physiomics plc Dr Peter Sargent, CEO	+44 (0) 1235 841575
Hybridan LLP (Broker) Claire Louise Noyce	+44 (0) 203 764 2341
Strand Hanson Limited (NOMAD) James Dance & James Bellman	+44 (0) 20 7409 3494
Winterflood Retail Access Platform Sophia Bechev & Kaitlan Billings	WRAP@winterflood.com +44 (0)203 8100 0000

Further information on the Company can be found on its website at www.physiomics.co.uk

The Company's LEI is 213800A71DSZ6ABMTQ91.

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.